Yoshifuji Matsumoto

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados et al. · The Lancet · 2018 · 359 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +14

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial

Atul Deodhar, Désirée van der Heijde, Lianne S. Gensler et al. · The Lancet · 2019 · 214 citations

Medicine, Clinical Sciences, Pharmacotherapy +10

Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan: The first government‐supported nationwide survey

S Kobayashi, Tetsuro Yano, Yoshifuji Matsumoto et al. · Arthritis Care & Research · 2003 · 191 citations

Medicine, Clinical Sciences, Internal Medicine +13

The Efficacy of Therapeutic Plasmapheresis for the Treatment of Fatal Hemophagocytic Syndrome: Two Case Reports

Yoshifuji Matsumoto, Daio Naniwa, S. Banno et al. · Therapeutic Apheresis · 1998 · 88 citations

Medicine, Hematology, Pathology +17

An Epidemiologic Internet Survey of Fibromyalgia and Chronic Pain in Japan

Ikuro Nakamura, Kenya Nishioka, Chie Usui et al. · Arthritis Care & Research · 2014 · 69 citations

Medicine, Chronic Disease Control, Health Assessment +14